Caleah Kitchens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Caleah Kitchens has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jesse Joshua Smith
Department of Surgery, Colorectal Surgery Service, Memorial Sloan Kettering Cancer Center, New York, USA
2 shared publications - Andrea Cercek
Memorial Sloan Kettering Cancer Center
1 shared publication - Ardaman Shergill
Department of Medicine, Section of Hematology/Oncology, University of Chicago, University of Chicago Medicine, Chicago, IL, USA.
1 shared publication Aron Bercz
Memorial Sloan Kettering Cancer Center , New York, NY
1 shared publication- Aron Bercz
Department of Surgery, Colorectal Service Memorial Sloan Kettering Cancer Center New York New York USA
1 shared publication - Arvind Dasari
Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
1 shared publication
Latest Publications
- Open Access
- 24 August 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (1) , 145-153
Integrating Immune Checkpoint Inhibitors With Total Neoadjuvant Therapy in Proficient Mismatch Repair Rectal Cancer
The management of locally advanced rectal cancer (LARC) has evolved with the adoption of total neoadjuvant therapy (TNT), integrated chemoradiotherapy (CRT) or short‐course radiotherapy (SCRT) with systemic chemotherapy. Although immune checkpoint inhibitors (ICIs) show remarkable efficacy in mismatch repair‐deficient/MSI‐H colorectal cancer, their role in proficient mismatch repair (pMMR)/microsatellite stable (MSS) tumors remains limited owing to poor immunogenicity. CRT or SCRT has emerged as a promising immunomodulator capable of converting “cold” pMMR/MSS tumors into “hot” immune‐responsive environments, thereby enhancing antigen presentation and PD‐L1 expression. Although CRT‐ICI combinations have achieved modest efficacy with pathological complete response (pCR) rates generally plateauing around 40%, recent studies that incorporate ICIs into TNT (TNT‐ICI), notably UNION, TORCH, and PRECAM, have achieved higher pCR and clinical complete response (cCR) rates (40%–60%). Focusing exclusively on TNT, this review underscores that optimal sequencing and chemotherapy intensity are paramount for maximizing synergy while limiting lymphodepletion. It consolidates the growing clinical evidence and mechanistic rationale for integrating ICIs into TNT, for pMMR/MSS LARC, and delineates a pathway toward higher pCR and cCR rates alongside organ‐preserving treatment strategies.
- 24 August 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (1) , 145-153
Open AccessIntegrating Immune Checkpoint Inhibitors With Total Neoadjuvant Therapy in Proficient Mismatch Repair Rectal Cancer
The management of locally advanced rectal cancer (LARC) has evolved with the adoption of total neoadjuvant therapy (TNT), integrated chemoradiotherapy (CRT) or short‐course radiotherapy (SCRT) with systemic chemotherapy. Although immune checkpoint inhibitors (ICIs) show remarkable efficacy in mismatch repair‐deficient/MSI‐H colorectal cancer, their role in proficient mismatch repair (pMMR)/microsatellite stable (MSS) tumors remains limited owing to poor immunogenicity. CRT or SCRT has emerged as a promising immunomodulator capable of converting “cold” pMMR/MSS tumors into “hot” immune‐responsive environments, thereby enhancing antigen presentation and PD‐L1 expression. Although CRT‐ICI combinations have achieved modest efficacy with pathological complete response (pCR) rates generally plateauing around 40%, recent studies that incorporate ICIs into TNT (TNT‐ICI), notably UNION, TORCH, and PRECAM, have achieved higher pCR and clinical complete response (cCR) rates (40%–60%). Focusing exclusively on TNT, this review underscores that optimal sequencing and chemotherapy intensity are paramount for maximizing synergy while limiting lymphodepletion. It consolidates the growing clinical evidence and mechanistic rationale for integrating ICIs into TNT, for pMMR/MSS LARC, and delineates a pathway toward higher pCR and cCR rates alongside organ‐preserving treatment strategies.
- 19 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1421-1428
Utilizing Patient Input in Rectal Cancer Trial Design
Background: The treatment of locally advanced rectal cancer now includes “watch-and-wait” (WW) management for patients who exhibit a clinical complete response (cCR) to total neoadjuvant therapy (TNT). We assessed patients’ knowledge and preferences regarding WW with the goal of incorporating patient input into clinical trial design. Methods: Rectal cancer patients in advocacy groups (COLONTOWN/Rectalburgh and Fight CRC) were surveyed regarding perceptions about treatment strategies, tolerable risks of treatment failure, and preferences on clinical trial design. Surveys were initially distributed in 2019, with the shift toward WW prompting re-survey of select questions in 2023. Results: All respondents preferred enrollment in trials that incorporated patient input. Most respondents (76%) preferred treatment that incorporated chemotherapy escalation over radiation escalation. Furthermore, when presented with a hypothetical patient who developed a cCR after chemoradiation (without the option for WW), 58% of patients chose surgical treatment (with 100% risk of permanent ostomy and 80% chance of cure) over omission of surgery (with <80% chance of cure). In contrast, when the hypothetical patient developed a cCR after TNT (with an option for WW), 82% of patients opted for selective WW over surgery. Conclusions: This work successfully integrated patient advocacy groups as a resource for obtaining patient input. Surveys revealed patients had a strong preference for chemotherapy escalation, for selective WW when offered, and for incorporation of input into future clinical trial design. These findings describe how well-informed patients approach complex medical decision-making and serve as a starting point for future studies seeking to incorporate patient voices.
- 19 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (7) , 1421-1428
Utilizing Patient Input in Rectal Cancer Trial Design
Background: The treatment of locally advanced rectal cancer now includes “watch-and-wait” (WW) management for patients who exhibit a clinical complete response (cCR) to total neoadjuvant therapy (TNT). We assessed patients’ knowledge and preferences regarding WW with the goal of incorporating patient input into clinical trial design. Methods: Rectal cancer patients in advocacy groups (COLONTOWN/Rectalburgh and Fight CRC) were surveyed regarding perceptions about treatment strategies, tolerable risks of treatment failure, and preferences on clinical trial design. Surveys were initially distributed in 2019, with the shift toward WW prompting re-survey of select questions in 2023. Results: All respondents preferred enrollment in trials that incorporated patient input. Most respondents (76%) preferred treatment that incorporated chemotherapy escalation over radiation escalation. Furthermore, when presented with a hypothetical patient who developed a cCR after chemoradiation (without the option for WW), 58% of patients chose surgical treatment (with 100% risk of permanent ostomy and 80% chance of cure) over omission of surgery (with <80% chance of cure). In contrast, when the hypothetical patient developed a cCR after TNT (with an option for WW), 82% of patients opted for selective WW over surgery. Conclusions: This work successfully integrated patient advocacy groups as a resource for obtaining patient input. Surveys revealed patients had a strong preference for chemotherapy escalation, for selective WW when offered, and for incorporation of input into future clinical trial design. These findings describe how well-informed patients approach complex medical decision-making and serve as a starting point for future studies seeking to incorporate patient voices.